Skip to main content
Top
Published in: Current Treatment Options in Neurology 2/2012

01-04-2012 | Cognitive Disorders (M Geschwind, Section Editor)

Therapeutics in Huntington’s Disease

Authors: Annie Killoran, MD, MSc, Kevin M. Biglan, MD, MPH

Published in: Current Treatment Options in Neurology | Issue 2/2012

Login to get access

Opinion statement

There is no specific treatment for Huntington’s disease (HD). Its many symptoms of motor, psychiatric, and cognitive deterioration are managed with symptomatic relief, rehabilitation, and support. The only drug approved by the US Food and Drug Administration (FDA) for the treatment of HD is an antichoreic agent, tetrabenazine, but this drug is used sparingly because of uneasiness regarding its propensity to cause depression and suicidality in this population, which is already at risk for these complications. Neuroleptics are still first-line treatments for chorea accompanied by comorbid depression and/or behavioral or psychotic symptoms, as is often the case. Psychiatric features, which have a significant impact on a patient’s professional and personal life, often become the major focus of management. In addition to neuroleptics, commonly used medications include antidepressants, mood stabilizers, anxiolytics, and psychostimulants. In contrast, few treatment options are available for cognitive impairment in HD; this remains an important and largely unmet therapeutic need. HD patients typically lack insight into their disease manifestations, failing to recognize their need for treatment, and possibly even arguing against it. Multipurpose medications are employed advantageously to simplify the medication regimen, so as to facilitate compliance and not overwhelm the patient. For example, haloperidol can be prescribed for a patient with chorea, agitation, and anorexia, rather than targeting each symptom with a different drug. This approach also limits the potential for adverse effects, which can be difficult to distinguish from the features of the disease itself. With HD’s complexity, it is best managed with a multidisciplinary approach that includes a movement disorders specialist, a genetic counselor, a mental health professional, a physical therapist, and a social worker for support and coordination of services. As the disease progresses, there may be need for other specialists, such as a speech and occupational therapist, a nutritionist for weight loss, and ultimately, a palliative care specialist.
Literature
1.
go back to reference Huntington G. On chorea. Med Surg Rep. 1872;26:317–21. Huntington G. On chorea. Med Surg Rep. 1872;26:317–21.
2.
go back to reference The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–83.CrossRef The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–83.CrossRef
3.
go back to reference Hodgson JG, Agopyan N, Gutekunst CA, et al. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999;23:181–92.PubMedCrossRef Hodgson JG, Agopyan N, Gutekunst CA, et al. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999;23:181–92.PubMedCrossRef
5.•
go back to reference Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington’s disease. Mov Disord. 2011 Oct 13 (Epub ahead of print). This is a recent detailed review of the pharmacological aspects of the medications currently used in HD and of those being evaluated for future use. Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington’s disease. Mov Disord. 2011 Oct 13 (Epub ahead of print). This is a recent detailed review of the pharmacological aspects of the medications currently used in HD and of those being evaluated for future use.
6.
go back to reference Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5:181–97.PubMedCrossRef Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5:181–97.PubMedCrossRef
7.
go back to reference Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington’s disease. Mov Disord. 2008;23:1491–504.PubMedCrossRef Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington’s disease. Mov Disord. 2008;23:1491–504.PubMedCrossRef
8.•
go back to reference Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98.PubMedCrossRef Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98.PubMedCrossRef
9.•
go back to reference Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.CrossRef Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.CrossRef
10.
go back to reference Poon LH. Role of tetrabenazine for Huntington’s disease-associated chorea. Ann Pharmacother. 2010;44:1080–9.PubMedCrossRef Poon LH. Role of tetrabenazine for Huntington’s disease-associated chorea. Ann Pharmacother. 2010;44:1080–9.PubMedCrossRef
11.
go back to reference Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol. 2002;25:263–5.PubMedCrossRef Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol. 2002;25:263–5.PubMedCrossRef
12.
go back to reference Squitieri F, Cannella M, Piorcellini A, et al. Shortterm effects of olanzapine in Huntington’s disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:69–72.PubMed Squitieri F, Cannella M, Piorcellini A, et al. Shortterm effects of olanzapine in Huntington’s disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:69–72.PubMed
13.
go back to reference Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19:101–3.PubMedCrossRef Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19:101–3.PubMedCrossRef
14.
go back to reference Duff K, Beglinger LJ, O’Rourke ME, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry. 2008;20:1–3.PubMedCrossRef Duff K, Beglinger LJ, O’Rourke ME, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry. 2008;20:1–3.PubMedCrossRef
15.
go back to reference Giménez-Roldán S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia. 1989;4:282–7.PubMed Giménez-Roldán S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia. 1989;4:282–7.PubMed
16.
go back to reference Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust. 1976;1:225–7.PubMed Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust. 1976;1:225–7.PubMed
17.
go back to reference Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics. 2006;47:70–2.PubMedCrossRef Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics. 2006;47:70–2.PubMedCrossRef
18.
go back to reference Saft C, Lauter T, Kraus PH, et al. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington’s Disease patients: a case series. BMC Neurol. 2006;6:11.PubMedCrossRef Saft C, Lauter T, Kraus PH, et al. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington’s Disease patients: a case series. BMC Neurol. 2006;6:11.PubMedCrossRef
19.
go back to reference Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington’s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25:46–50.PubMedCrossRef Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington’s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25:46–50.PubMedCrossRef
20.
go back to reference Duan W, Peng Q, Masuda N, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington’s disease. Neurobiol Dis. 2008;30:312–22.PubMedCrossRef Duan W, Peng Q, Masuda N, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington’s disease. Neurobiol Dis. 2008;30:312–22.PubMedCrossRef
21.
go back to reference Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol. 2004;55:590–4.PubMedCrossRef Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol. 2004;55:590–4.PubMedCrossRef
22.
go back to reference de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov Disord. 2004;19:1516–8.PubMedCrossRef de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov Disord. 2004;19:1516–8.PubMedCrossRef
23.
go back to reference de Tommaso M, Difruscolo O, Sciruicchio V, et al. Two years’ follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30:43–6.PubMedCrossRef de Tommaso M, Difruscolo O, Sciruicchio V, et al. Two years’ follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30:43–6.PubMedCrossRef
24.
go back to reference Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67:1268–71.PubMedCrossRef Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67:1268–71.PubMedCrossRef
25.
go back to reference Brown GR. The use of methylphenidate for cognitive decline associated with HIV disease. Int J Psychiatry Med. 1995;25:21–37.PubMedCrossRef Brown GR. The use of methylphenidate for cognitive decline associated with HIV disease. Int J Psychiatry Med. 1995;25:21–37.PubMedCrossRef
26.
go back to reference Brown TE, Landgraf JM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med. 2010;122:42–51.PubMedCrossRef Brown TE, Landgraf JM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med. 2010;122:42–51.PubMedCrossRef
27.
go back to reference Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29:484–7.PubMedCrossRef Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29:484–7.PubMedCrossRef
28.
29.
go back to reference Burbaud P, Ducerf C, Cugy E, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258:1670–5.PubMedCrossRef Burbaud P, Ducerf C, Cugy E, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258:1670–5.PubMedCrossRef
30.
go back to reference Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington’s disease. Parkinsonism Relat Disord. 2007;13:453–4.PubMedCrossRef Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington’s disease. Parkinsonism Relat Disord. 2007;13:453–4.PubMedCrossRef
31.
go back to reference Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57:397–404. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57:397–404.
32.
go back to reference Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology. 2006;66:250–2.PubMedCrossRef Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology. 2006;66:250–2.PubMedCrossRef
33.
go back to reference de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. on behalf of the MermaiHD study investigators. Pridopidine for the treatment of motor function in patients with Huntington’s disease: a phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2011;10:1049–57.PubMedCrossRef de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. on behalf of the MermaiHD study investigators. Pridopidine for the treatment of motor function in patients with Huntington’s disease: a phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2011;10:1049–57.PubMedCrossRef
34.
go back to reference Zeef D, Schaper F, Vlamings R, et al. Deep brain stimulation in Huntington’s disease: the current status. Open Neurosurg J. 2011;4:7–10.CrossRef Zeef D, Schaper F, Vlamings R, et al. Deep brain stimulation in Huntington’s disease: the current status. Open Neurosurg J. 2011;4:7–10.CrossRef
35.
go back to reference Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington’s disease. Neurology. 2002;58:687–95.PubMed Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington’s disease. Neurology. 2002;58:687–95.PubMed
36.
go back to reference Southwell AL, Patterson PH. Gene therapy in mouse models of Huntington disease. Neuroscientist. 2011;17:153–62.PubMedCrossRef Southwell AL, Patterson PH. Gene therapy in mouse models of Huntington disease. Neuroscientist. 2011;17:153–62.PubMedCrossRef
37.
go back to reference Jongen P, Renier W, Gabreels F. Seven cases of Huntington’s disease in childhood and levodopa induced improvement in the hypokinetic—rigid form. Clin Neurol Neurosurg. 1980;82:251–61.PubMedCrossRef Jongen P, Renier W, Gabreels F. Seven cases of Huntington’s disease in childhood and levodopa induced improvement in the hypokinetic—rigid form. Clin Neurol Neurosurg. 1980;82:251–61.PubMedCrossRef
38.
go back to reference Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord. 2005;20:1610–4.PubMedCrossRef Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord. 2005;20:1610–4.PubMedCrossRef
39.
go back to reference de Tommaso M, Di Fruscolo O, Sciruicchio V, et al. Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol. 2005;28:280–4.PubMedCrossRef de Tommaso M, Di Fruscolo O, Sciruicchio V, et al. Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol. 2005;28:280–4.PubMedCrossRef
Metadata
Title
Therapeutics in Huntington’s Disease
Authors
Annie Killoran, MD, MSc
Kevin M. Biglan, MD, MPH
Publication date
01-04-2012
Publisher
Current Science Inc.
Published in
Current Treatment Options in Neurology / Issue 2/2012
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-012-0165-x

Other articles of this Issue 2/2012

Current Treatment Options in Neurology 2/2012 Go to the issue

Critical Care Neurology (K Sheth, Section Editor)

Hypothermia and Ischemic Stroke

Critical Care Neurology (K Sheth, Section Editor)

Treatment of Neurocritical Care Emergencies in Pregnancy

Critical Care Neurology (K Sheth, Section Editor)

Statins and Anti-Inflammatory Therapies for Subarachnoid Hemorrhage

Critical Care Neurology (K Sheth, Section Editor)

Acute Treatment Options for Spinal Cord Injury